Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD

Blood

Volumn 120, Issue 25, 2012, Pages 5089-5090

  De Masson, Adèle ^a   Bouaziz, Jean David ^a   De Latour, Régis Peffault ^b   Wittnebel, Sebastian ^c   Ribaud, Patricia ^b   Rubio, Marie Thérèse ^d   Micol, Jean Baptiste ^c   Suarez, Felipe ^e   Nguyen, Stéphanie ^f   Dalle, Jean Hugues ^g   Yakouben, Karima ^g   Robin, Marie ^b   Xhaard, Aliénor ^b   Adès, Lionel ^b   Bourhis, Jean Henri ^c   Rybojad, Michel ^a   Bagot, Martine ^a   Socié, Gérard ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; RITUXIMAB; THALIDOMIDE;

ADOLESCENT; ADULT; AGED; BODY SURFACE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONSCIOUSNESS; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FASCIITIS; FEMALE; FLUID RETENTION; HUMAN; LETTER; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SCHOOL CHILD; SCLERODERMA; SIDE EFFECT; SKIN ULCER; TREATMENT RESPONSE;

EID: 84871097041     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-453928     Document Type: Letter

References (6)

1. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114(3):719-722.
2. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709-718.
3. Chen GL, Arai S, Flowers ME, et al. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 2011;118(15):4070-4078.
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
5. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient reported skin score and outcome: results from the Chronic GVHD Consortium. Blood. 2012;120(13):2545-2552.
6. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110(1):237-241. (Pubitemid 47026840)